Phospholipid metabolism and effectiveness of a glycoprotein IIb/IIIa receptor blocker tirofiban in patients with acute coronary syndrome without ST segment elevation
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Aim. To study the effects of tirofiban, a glycoprotein IIb/IIIa receptor blocker, on platelet (PL) phospholipids (PhL) in patients with acute coronary syndrome (ACS).
Material and methods. The study included 55 ACS patients without ST segment elevation (↓ST), receiving standard therapy; 26 participants were administered tirofiban. The control group included 23 healthy volunteers, without any cardiovascular disease. In all participants, PL PhL characteristics were assessed at baseline, at Day 3 and Days 7-10.
Results. In ACS patients, both qualitative and quantitative changes in PL PhL metabolism were observed, which could result in disturbed PL hemostasis. The main manifestation of these disturbances was increased lysophosphatidyl choline (LFS) level in PL membranes. Disturbed PL PhL metabolism was observed in all ACS patients, being maximally manifested at baseline.
Conclusion. Tirofiban therapy, as a part of standard ACS↓ST treatment, improved PhL composition of PL membranes and beneficially affected PL hemostasis.
About the Authors
Sh. I. Makhamatova
Republican Research Centre for Emergency Medicine
Uzbekistan
Uzbekistan
Tashkent
M. L. Kenzhaev
Republican Research Centre for Emergency Medicine
Uzbekistan
Uzbekistan
Tashkent
B. A. Alyavi
Republican Research Centre for Emergency Medicine
Uzbekistan
Uzbekistan
Tashkent
Kh. A. Mamatkulov
Republican Research Centre for Emergency Medicine
Uzbekistan
Uzbekistan
Tashkent
L. Sh. Davlyatova
Republican Research Centre for Emergency Medicine
Uzbekistan
Uzbekistan
Tashkent
References
1. Gratsianskii N.A. K vykhodu rekomendatsii Vserossiiskogo nauchnogo obshchestva kardiologov. Lechenie ostrogo koronarnogo sindroma bez stoikikh pod"emov segmenta ST na EKG. Kardiologiya 2002; 1: 4-9.
2. Gratsianskii N.A. Vozmozhnaya korrektsiya algoritma lecheniya ostrogo koronarnogo sindroma bez pod"emov segmenta ST na elektrokardiogramme. Cons med 2007; 2(1): 1-11.
3. Kokhanskii M.E. Vliyanie tromboliticheskoi terapii s ispol'zovaniem razlichnykh antikoagulyantov i koronarnoi angioplastiki na klinicheskoe techenie infarkta mio-karda. Avtoref diss kand med nauk. Sankt-Peterburg 2003.
4. Simovan'yan E.M., Alimova E.K. Lipidnyi sostav membran eritrotsitov syvorotki krovi pri meningokokkovoi infektsii u detei. Vopr med khimii 1984; 2: 28-32.
5. 5.Tulabaeva G.M. Kliniko-patogeneticheskaya kharakteristika trombotsitarnogo zvena gemostaza pri infarkte miokarda. Diss dok med nauk. Tashkent 2004.
6. Shalaev S.V. Antitrombotsitarnye sredstva v meditsinskom lechenii ostrykh koronarnykh sindromov. Farmateka 2003; 312: 94.
7. Eet Erdal Kavusugli. Fosfolipidy - “novyi kardiovaskulyarnyi marker”. Am J Cardiol 2007; 12: 1739-43.
8. Bertrand ME. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force on Management of acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2002; 23: 1809-40.
9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). JACC 2000; 36: 970-1062.
10. Cahff RM. Glycoprotein IIb/IIIa blockade and thrombolytics early lessons from the SPEED and GUSTO IV trials. Am Heart J 1999; 138: S12-5.
11. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50, 310-8.
12. Kristensen SD, Lassen JF, Ravn HB. Pathophysiology of coronary thrombosis. Semin Interv Cardiol 2000; 5(3): 109-15.
13. 13.Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol 2000; 86(8B): 3J-8J, discussion 8J-9.
14. Reutelingsperger CPM, van Heerde WL, Annexin V. The regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Lafe Sci 1997; 53: 527-32.
15. Rosenschein U. Introduction. Intracoronary thrombosis is the largest single cause of morbidity and mortality in the Western World. Semin Interv Cardiol 2000; 5(3): 107.
Review
For citations:
Makhamatova Sh.I., Kenzhaev M.L., Alyavi B.A., Mamatkulov Kh.A., Davlyatova L.Sh. Phospholipid metabolism and effectiveness of a glycoprotein IIb/IIIa receptor blocker tirofiban in patients with acute coronary syndrome without ST segment elevation. Cardiovascular Therapy and Prevention. 2009;8(6):29-34. (In Russ.)
Views:
693
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
